Nexsen (ASX: NXN) Adds 5%: How Far Can Its Point-of-Care Diagnostics Expansion Go?

Aditi Sarkar

01 September 2026 01:57 PM AEST

Nexsen (ASX: NXN) Adds 5%: How Far Can Its Point-of-Care Diagnostics Expansion Go?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Nexsen has established a strategic collaboration with Gleneagles Hospital Hong Kong.
The company is expanding its rapid point-of-care diagnostics platform in Asia.
Nexsen secured AUD 1.5mn in non-dilutive ARC funding for Manufacturing in June.
NXN shares rose 5.00% to AUD 0.21 at the time of writing on 1 September 2026.

Nexsen (ASX: NXN) shares rose 5.00% to AUD 0.21 at the time of writing on 1 September 2026. Nexsen Limited (ASX: NXN) is building its healthcare platform through clinical, manufacturing and regional partnerships. Its 2026 announcements have highlighted expansion across Asia-Pacific, with the company developing rapid point-of-care diagnostic products designed to bring testing closer to patients. The company’s disclosures cover both clinical validation and the infrastructure needed to support commercial activity.

Hospital Partnership Opens a Clinical Pathway

In May, Nexsen announced a binding term sheet with GHK Hospital Limited, operator of Gleneagles Hospital Hong Kong. The collaboration establishes a framework for clinical validation, real-world data generation and potential commercialisation of Nexsen’s rapid point-of-care diagnostics platform. The hospital is a 500-bed multi-specialty private tertiary hospital. The agreement provides the disclosed framework for Nexsen to work within a hospital setting in Asia.

Manufacturing Capacity Also Advances

Nexsen announced AUD 1.5mn of non-dilutive ARC funding in June to support manufacturing. The company also announced the launch of a Hong Kong Facility and pipeline expansion in July. Together, these disclosures show the company progressing both market access and manufacturing capability. The separate announcements form part of the company’s wider Asia-Pacific execution program.

NXN Share Price at the Time of Writing

At the time of writing on 1 September 2026, NXN shares rose 5.00% to AUD 0.21. The company’s disclosed focus remains on diagnostics validation, manufacturing and Asia-Pacific expansion. Future updates will show how these partnerships develop within the company’s stated strategy.

FAQs

Q: What does Nexsen (ASX: NXN) develop?

A: Nexsen develops rapid point-of-care diagnostic products.

Q: Who is Nexsen’s Hong Kong hospital partner?

A: Nexsen entered a binding term sheet with GHK Hospital Limited, operator of Gleneagles Hospital Hong Kong.

Q: What funding did Nexsen receive for manufacturing?

A: Nexsen announced AUD 1.5mn in non-dilutive ARC funding for manufacturing.

Q: What was the NXN share price at the time of writing?

A: NXN traded at AUD 0.21 at the time of writing on 1 September 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.